ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?

• Main Authors: Bieke Soen, Niels Vandamme, Geert Berx, Jürg Schwaller, Pieter Van Vlierberghe, Steven Goossens
• Format: Article
• Language: English
• Published: Wolters Kluwer 2018-06-01
• Series: HemaSphere
• Online Access: http://journals.lww.com/10.1097/HS9.0000000000000043

Abstract. ZEB1 and ZEB2 play pivotal roles in solid cancer metastasis by allowing cancer cells to invade and disseminate through the transcriptional regulation of epithelial-to-mesenchymal transition. ZEB expression is also associated with the acquisition of cancer stem cell properties and therapy resistance. Consequently, expression levels of ZEB1/2 and of their direct target genes are widely seen as reliable prognostic markers for solid tumor aggressiveness and cancer patient outcome. Recent loss-of-function mouse models demonstrated that both ZEBs are also essential hematopoietic transcription factors governing blood lineage commitment and fidelity. Interestingly, both gain- and loss-of-function mutations have been reported in multiple hematological malignancies. Combined with emerging functional studies, these data suggest that ZEB1 and ZEB2 can act as tumor suppressors and/or oncogenes in blood borne malignancies, depending on the cellular context. Here, we review these novel insights and discuss how balanced expression of ZEB proteins may be essential to safeguard the functionality of the immune system and prevent leukemia.